ИСТИНА

Event-related potentials (P300) in patients with cerebrovascular diseases combined with the metabolic syndrome. *A. Chatskaya1, V. Gnezditskiy1, O. Korepina1, M. Tanashyan1 1Research Center of Neurology, Russian Academy of Medical Sciences, department of neurophysiology , Moscow, Russian Federation Question Metabolic syndrome (MS) raises the risk of cerebrovascular diseases (CVD). Cognitive decline is one of the MS complications. Neurophysiologic method that can estimate the cognitive dysfunction is event-related potentials (P300). The aim of our study was to investigate the features of the P300 in patients with CVD caused by the MS and compare these results with clinical data. Methods We examined 52 patients with a CVD and the MS, mean age 65±7, 14 men and 38 women. 31 patients suffered from chronic brain ischemia and 21 patients had stroke in anamnesis All patients were divided into two groups: the MS combined with diabetes mellitus type 2 (DM 2) 28 persons and without it - 24 persons. Control group consisted healthy subjects, n=21. Patients were tested by Montreal cognitive assessment (MoCA). P300 were enrolled with hearing and counting the rare (target) tones and next pressing the button on the rare tones. Results Most of patients from the both groups complained on a memory loss. The mean MoCA score in group of patients without DM 2 was 24.6 and in group with DM 2 was 22.8. P300 responses in both groups of patients were not consistent, the counting were inaccurate, there were lower percentage of the right pressing the button, and prolonged reaction time (RT) on the button pressing, especially in patients with DM 2. Also, latency of the P3 was more prolonged and amplitude of the N2/P3 was lower in patients from both groups in comparison with control group (p<0.005). The significant differences of P300 indices among groups of patients were revealed in latency of the P3 and the RT (p<0,05) Conclusion Patients from both groups with CVD combined with the MS had cognitive decline, especially in group with DM type 2 that was confirmed by P300 data. P300 is important in diagnostic of cognitive decline in patients with CD caused by MS, especially at an early stage of the disease because DM 2 leads to more severe cognitive impairment.